153 related articles for article (PubMed ID: 27847402)
1. Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades.
Dyachenko L; Havrysh K; Lytovchenko A; Dosenko I; Antoniuk S; Filonenko V; Kiyamova R
Dis Markers; 2016; 2016():5128720. PubMed ID: 27847402
[No Abstract] [Full Text] [Related]
2. Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas.
Kostianets O; Antoniuk S; Filonenko V; Kiyamova R
Diagn Pathol; 2012 Nov; 7():161. PubMed ID: 23181716
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Chapman C; Murray A; Chakrabarti J; Thorpe A; Woolston C; Sahin U; Barnes A; Robertson J
Ann Oncol; 2007 May; 18(5):868-73. PubMed ID: 17347129
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels and clinical implications of epithelial membrane antigen and cytokeratin-1 in women with breast cancer: can their ratio improve the results?
Attallah AM; El-Far M; Omran MM; Abdallah SO; El-Desouky MA; El-Dosoky I; Abdelrazek MA; Attallah AA; Elweresh MA; Abdel Hameed GE; Shawki HA; Salama KS; El-Waseef AM
Tumour Biol; 2014 Nov; 35(11):10737-45. PubMed ID: 25073515
[TBL] [Abstract][Full Text] [Related]
6. Enhanced humoral immunity in breast cancer patients with high serum concentration of anti-HER2 autoantibody.
Sato Y; Shimoda M; Sota Y; Miyake T; Tanei T; Kagara N; Naoi Y; Kim SJ; Noguchi S; Shimazu K
Cancer Med; 2021 Feb; 10(4):1418-1430. PubMed ID: 33506656
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
[TBL] [Abstract][Full Text] [Related]
8. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
9. Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis.
Wang Y; Wang P; Liu M; Zhang X; Si Q; Yang T; Ye H; Song C; Shi J; Wang K; Wang X; Zhang J; Dai L
J Immunol Methods; 2021 May; 492():112991. PubMed ID: 33587914
[TBL] [Abstract][Full Text] [Related]
10. Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens.
Evans RL; Pottala JV; Egland KA
Cancer Prev Res (Phila); 2014 May; 7(5):545-55. PubMed ID: 24641868
[TBL] [Abstract][Full Text] [Related]
11. Panel of SEREX-defined antigens for breast cancer autoantibodies profile detection.
Kostianets O; Shyyan M; Antoniuk SV; Filonenko V; Kiyamova R
Biomarkers; 2017 Mar; 22(2):149-156. PubMed ID: 27775439
[TBL] [Abstract][Full Text] [Related]
12. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
13. The network of antigen-antibody reactions in adult women with breast cancer or benign breast pathology or without breast pathology.
Romo-González T; Esquivel-Velázquez M; Ostoa-Saloma P; Lara C; Zentella A; León-Díaz R; Lamoyi E; Larralde C
PLoS One; 2015; 10(3):e0119014. PubMed ID: 25781932
[TBL] [Abstract][Full Text] [Related]
14. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression.
Volkmann M; Sinn HP; Gaugel D; Frey M; Hajjar Y; Ludwig J; Hänsel S; Bastert G; Wallwiener D; Fiehn W; Zentgraf H; Huober J
Oncology; 2002; 63(3):297-305. PubMed ID: 12381910
[TBL] [Abstract][Full Text] [Related]
15. Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.
Kulić A; Sirotković-Skerlev M; Jelisavac-Cosić S; Herceg D; Kovac Z; Vrbanec D
Med Oncol; 2010 Sep; 27(3):887-93. PubMed ID: 19763913
[TBL] [Abstract][Full Text] [Related]
16. Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach.
Kiyamova R; Kostianets O; Malyuchik S; Filonenko V; Usenko V; Gurtovyy V; Khozayenko Y; Antonuk S; Old L; Gout I
Mol Biotechnol; 2010 Oct; 46(2):105-12. PubMed ID: 20440581
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies as potential biomarkers for breast cancer.
Zhong L; Ge K; Zu JC; Zhao LH; Shen WK; Wang JF; Zhang XG; Gao X; Hu W; Yen Y; Kernstine KH
Breast Cancer Res; 2008; 10(3):R40. PubMed ID: 18460216
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.
Liu X; Chai Y; Li J; Ren P; Liu M; Dai L; Qian W; Li W; Zhang JY
Tumour Biol; 2014 Mar; 35(3):2661-7. PubMed ID: 24399648
[TBL] [Abstract][Full Text] [Related]
19. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.
Alper O; Stetler-Stevenson WG; Harris LN; Leitner WW; Ozdemirli M; Hartmann D; Raffeld M; Abu-Asab M; Byers S; Zhuang Z; Oldfield EH; Tong Y; Bergmann-Leitner E; Criss WE; Nagasaki K; Mok SC; Cramer DW; Karaveli FS; Goldbach-Mansky R; Leo P; Stromberg K; Weil RJ
Cancer Sci; 2009 Sep; 100(9):1748-56. PubMed ID: 19594548
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a panel of tumor-associated antigens in breast cancer.
Pagaza-Straffon C; Marchat LA; Herrera L; Díaz-Chávez J; Avante MG; Rodríguez YP; Arreola MC; López-Camarillo C
Cancer Biomark; 2020; 27(2):207-211. PubMed ID: 31839604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
